KCK start-up looking to tap $14B ADHD drug market

AUGUST 18, 2017 10:34 AM Experts on attention deficit hyperactivity disorder, or ADHD, are converging on Kansas City this weekend to meet with a Kansas native who has returned from the East Coast looking to build a drug company that can tap into a $14 billion market for treating the condition. Shane Schaffer, the CEO of Cingulate Therapeutics, said this weekend’s meeting of the company’s seven-member scientific advisory board will include experts from the United States, Canada and Scotland. “We’re definitely excited to bring these people into Kansas City and most of them have never been here before,” Schaffer said…. Read the full article

Cingulate Therapeutics Announces Expansion to Accommodate Growth

Kansas City, KS – (June 15, 2017) – Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that it has moved the location of its Kansas City headquarters. Cingulate previously had offices at the University of Kansas Bioscience and Technology Business Center in Kansas City, KS. The move is intended to accommodate Cingulate’s growth in transition into a clinical stage development company. Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 and CTX-1302, for the treatment of Attention Deficit/Hyperactivity Disorder… Read the full article

Cingulate Therapeutics Initiates First Human Clinical Trial

Dosing Underway in Proof of Concept Trial for CTX-1301 Kansas City, KS – (May 31, 2017) – Cingulate Therapeutics, LLC, a privately held biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), is proud to announce its transition to a clinical stage development company with the initiation of dosing in its Proof of Concept Trial for CTX-1301, one of two (2) proprietary, first-line stimulant medications the Company is developing for the treatment of ADHD. The four-week human clinical trial of CTX-1301 is being conducted in Glasgow, Scotland by its development… Read the full article

Kansas Startups Take Awards at NCBiotech Ag Biotech Showcase

SUBMITTED BY JSHAMP ON FRI, 2017-05-12 14:24 By Allan Maurer, NC Biotech Writer PrairieChar, a Kansas company developing a system to convert animal manure into useful products, won the $10,000 cash prize and $3,500 in legal and financial advice at the North Carolina Biotechnology Center’s 2017 Ag Biotech Entrepreneurial Showcase. Event sponsors Smith Anderson, the Raleigh-based law firm, and accounting firm Hughes Pittman Gupton, are providing the in-kind services. Integrated Animal Health, also based in Kansas, which finds and commercializes medicine and foods for pets and farm animals, won the $2,500 cash second prize. They were among 12 ag bio… Read the full article

Foster Care Technologies Joins Microsoft ISV Partner Program

Lawrence, KS – February 27, 2017 – Foster Care Technologies, LLC (FCT), the company behind the ECAP foster care Placement Matching System, is excited to announce it has joined Microsoft’s Independent Software Vendor (ISV) Partner Program. As an ISV partner, we will be working closely with Microsoft personnel, who will provide a variety of resources and information to help us expand our customer base, particularly among public government foster care agencies. We will continue to utilize Microsoft Azure as our data hosting service because of its reliability and data security. “Microsoft’s expertise and support will help us make ECAP available… Read the full article

Next

Ready to take your technology to the masses? Let’s do business.